New study aims to tailor ovarian cancer treatment for black women

NCT ID NCT06412120

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 23 times

Summary

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Niraparib works by blocking cancer cells from repairing their DNA, which can slow or stop tumor growth. Researchers will also study how genetic and environmental factors affect the drug's safety and side effects. About 70 participants will be enrolled to help improve treatment for this group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ahmadu Bello University Teaching Hospital (ABUTH)
RECRUITING

Zaria, Kaduna State, Nigeria

Contact Email: •••••@•••••

Contact
Broward Health
RECRUITING

Fort Lauderdale, Florida, 33316, United States

Contact Email: •••••@•••••

Contact
University of Miami
RECRUITING

Miami, Florida, 33136, United States

Contact

Contact

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER